Loading clinical trials...
Loading clinical trials...
Role of Gastrointestinal Endoscopy in Evaluation of Pediatric Failure to Thrive
This study aims to evaluate the diagnostic role of gastrointestinal endoscopy in children presenting with failure to thrive and its correlation with histopathology and other diagnostic modalities.
Failure to thrive (FTT) is a common and concerning clinical presentation in pediatric practice, characterized by inadequate growth or the inability to maintain expected weight and height percentiles (1). By accepted definitions, FTT can be defined as weight-for-age below the 5th percentile, or a drop of two major percentile lines on a standardized growth chart (2). It is not a diagnosis but rather a descriptive term that reflects an underlying issue with inadequate energy intake, absorption, or utilization. The causes of FTT are broad and often multifactorial, ranging from nutritional deficiencies and feeding difficulties to chronic infections, metabolic disorders, and gastrointestinal (GI) diseases. Among these, GI causes are particularly important, as they may be subtle, chronic, and potentially reversible with early diagnosis and appropriate management (3). Despite advances in nutritional support and non-invasive diagnostics, a subset of children with persistent FTT require further evaluation to identify underlying organic causes (4). Gastrointestinal endoscopy, including esophagogastroduodenoscopy (EGD) and colonoscopy, provides direct visualization, tissue sampling, and diagnosis of a wide spectrum of pathologies such as gastroesophageal reflux disease, eosinophilic esophagitis, celiac disease, inflammatory bowel disease, peptic ulcer disease, and malabsorptive disorders (5). Children presenting with FTT and associated gastrointestinal symptoms such as persistent vomiting, chronic diarrhea, abdominal pain, dysphagia, feeding intolerance, or hematemesis are particularly likely to benefit from gastrointestinal endoscopy (6). Even in the absence of overt GI symptoms, some children with unexplained FTT may harbor asymptomatic or minimally symptomatic conditions detectable only through endoscopic and histologic examination. Furthermore, gastrointestinal endoscopy can also help to rule out serious pathologies and provide reassurance to caregivers, allowing clinicians to focus on non-organic or psychosocial contributors to FTT when appropriate (7). Despite its clinical utility, the use of gastrointestinal endoscopy in evaluation of FTT must be carefully considered due to its invasive nature, the need for sedation or anesthesia, and potential complications (8). Therefore, patient selection and risk-benefit ratio assessment are crucial. The decision to perform gastrointestinal endoscopy is often guided by a combination of clinical findings, laboratory data, growth patterns, and failure to respond to initial nutritional interventions (9).
Age
0 - 18 years
Sex
ALL
Healthy Volunteers
No
Start Date
September 20, 2025
Primary Completion Date
March 20, 2027
Completion Date
April 20, 2027
Last Updated
September 8, 2025
50
ESTIMATED participants
Lead Sponsor
Assiut University
NCT07060846
NCT06884800
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions